Matching Items (3)
Filtering by
Description
Introduction: Human papillomavirus (HPV) infection is seen in up to 90% of cases of cervical cancer, the third leading cancer cause of death in women. Current HPV screening focuses on only two HPV types and covers roughly 75% of HPV-associated cervical cancers. A protein based assay to test for antibody biomarkers against 98 HPV antigens from both high and low risk types could provide an inexpensive and reliable method to screen for patients at risk of developing invasive cervical cancer. Methods: 98 codon optimized, commercially produced HPV genes were cloned into the pANT7_cGST vector, amplified in a bacterial host, and purified for mammalian expression using in vitro transcription/translation (IVTT) in a luminescence-based RAPID ELISA (RELISA) assay. Monoclonal antibodies were used to determine immune cross-reactivity between phylogenetically similar antigens. Lastly, several protein characteristics were examined to determine if they correlated with protein expression. Results: All genes were successfully moved into the destination vector and 86 of the 98 genes (88%) expressed protein at an adequate level. A difference was noted in expression by gene across HPV types but no correlation was found between protein size, pI, or aliphatic index and expression. Discussion: Further testing is needed to express the remaining 12 HPV genes. Once all genes have been successfully expressed and purified at high concentrations, DNA will be printed on microscope slides to create a protein microarray. This microarray will be used to screen HPV-positive patient sera for antibody biomarkers that may be indicative of cervical cancer and precancerous cervical neoplasias.
ContributorsMeshay, Ian Matthew (Author) / Anderson, Karen (Thesis director) / Magee, Mitch (Committee member) / Katchman, Benjamin (Committee member) / Barrett, The Honors College (Contributor) / School of Life Sciences (Contributor)
Created2015-05
Description
microRNAs (miRNAs) are short ~22nt non-coding RNAs that regulate gene output at the post-transcriptional level. Via targeting of degenerate elements primarily in 3'untranslated regions (3'UTR) of mRNAs, miRNAs can target thousands of varying genes and suppress their protein translation. The precise mechanistic function and bio- logical role of miRNAs is not fully understood and yet it is a major contributor to a pleth- ora of diseases, including neurological disorders, muscular disorders, and cancer. Cer- tain model organisms are valuable in understanding the function of miRNA and there- fore fully understanding the biological significance of miRNA targeting. Here I report a mechanistic analysis of miRNA targeting in C. elegans, and a bioinformatic approach to aid in further investigation of miRNA targeted sequences. A few of the biologically significant mechanisms discussed in this thesis include alternative polyadenylation, RNA binding proteins, components of the miRNA recognition machinery, miRNA secondary structures, and their polymorphisms. This thesis also discusses a novel bioinformatic approach to studying miRNA biology, including computational miRNA target prediction software, and sequence complementarity. This thesis allows a better understanding of miRNA biology and presents an ideal strategy for approaching future research in miRNA targeting.
ContributorsWeigele, Dustin Keith (Author) / Mangone, Marco (Thesis director) / Katchman, Benjamin (Committee member) / Barrett, The Honors College (Contributor) / Department of Chemistry and Biochemistry (Contributor) / School of Life Sciences (Contributor)
Created2014-12
Description
As research progresses in the field of vaccinology, momentum has been gained to develop an efficacious and efficient dengue virus (DV) vaccine for all four serotypes. Dengue viral outbreaks across the world have called for a vaccine campaign. However, due to anti--"body dependent enhancement of infection, dengue virus has provided Researchers with challenges in developing a safe vaccine. Currently, there are a handful of vaccine candidates in clinical trial, but live chimeric attenuated vaccines dominate them. There are associated risks with using a live chimeric attenuated vaccine, but they are less expensive to generate and seem to provide a high immune response. Subunit vaccines are safer to use and can provide full protection for several years with then use of adjuvants and a booster shot. As a result, our lab is interested in pursuing this route to produce an effective dengue vaccine. The main target for a dengue subunit vaccine is the envelope protein, which is known to be an important recognition site by neutralizing antibodies. Therefore, expression of a recombinant envelope protein in a prokaryotic expression system is useful to study the immune response in vivo. This could be taken a step further and recombinant dengue envelope proteins can be expressed by a eukaryote to help generate hypotheses and insight to create a successful dengue virusn subunit vaccine.
ContributorsRiley, Jade (Author) / Reyes del Valle, Jorge (Thesis director) / Mason, Hugh (Committee member) / Katchman, Benjamin (Committee member) / Barrett, The Honors College (Contributor)
Created2013-05